Literature DB >> 33288229

Nuclear receptors: Key regulators of somatic cell functions in the ovulatory process.

Camilla H K Hughes1, Bruce D Murphy2.   

Abstract

The development of the ovarian follicle to its culmination by ovulation is an essential element of fertility. The final stages of ovarian follicular growth are characterized by granulosa cell proliferation and differentiation, and steroid synthesis under the influence of follicle-stimulating hormone (FSH). The result is a population of granulosa cells poised to respond to the ovulatory surge of luteinizing hormone (LH). Members of the nuclear receptor superfamily of transcription factors play indispensable roles in the regulation of these events. The key regulators of the final stages of follicular growth that precede ovulation from this family include the estrogen receptor beta (ESR2) and the androgen receptor (AR), with additional roles for others, including steroidogenic factor-1 (SF-1) and liver receptor homolog-1 (LRH-1). Following the LH surge, the mural and cumulus granulosa cells undergo rapid changes that result in expansion of the cumulus layer, and a shift in ovarian steroid hormone biosynthesis from estradiol to progesterone production. The nuclear receptor best associated with these events is LRH-1. Inadequate cumulus expansion is also observed in the absence of AR and ESR2, but not the progesterone receptor (PGR). The terminal stages of ovulation are regulated by PGR, which increases the abundance of the proteases that are directly responsible for rupture. It further regulates the prostaglandins and cytokines associated with the inflammatory-like characteristics of ovulation. LRH-1 regulates PGR, and is also a key regulator of steroidogenesis, cellular proliferation, and cellular migration, and cytoskeletal remodeling. In summary, nuclear receptors are among the panoply of transcriptional regulators with roles in ovulation, and several are necessary for normal ovarian function.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Follicle; Nuclear receptor; Ovulation; Steroidogenesis

Year:  2020        PMID: 33288229     DOI: 10.1016/j.mam.2020.100937

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  6 in total

1.  Steroidogenic Factor 1 Regulation of the Hypothalamic-Pituitary-Ovarian Axis of Adult Female Mice.

Authors:  Olivia E Smith; Vickie Roussel; Fanny Morin; Luisina Ongaro; Xiang Zhou; Micka C Bertucci; Daniel J Bernard; Bruce D Murphy
Journal:  Endocrinology       Date:  2022-04-01       Impact factor: 4.736

2.  DNA Methylation Profiles of Ovarian Granular Cells from Fluorosis Female Patients Suffering Reproductive Dysfunctions.

Authors:  Biqi He; Siyuan Dong; Qun Chen; Zhaoheng Dong; Chen Chen
Journal:  Biol Trace Elem Res       Date:  2021-10-22       Impact factor: 3.738

3.  Regulation of progesterone during follicular development by FSH and LH in sheep.

Authors:  Ziqiang Ding; Hongwei Duan; Wenbo Ge; Jianshu Lv; Jianlin Zeng; Wenjuan Wang; Tian Niu; Junjie Hu; Yong Zhang; Xingxu Zhao
Journal:  Anim Reprod       Date:  2022-07-11       Impact factor: 1.810

Review 4.  Hormone supply to the pituitary gland: A comprehensive investigation of female‑related tumors (Review).

Authors:  Wenxiu Tian; Huimin Qi; Zhimei Wang; Sen Qiao; Ping Wang; Junhong Dong; Hongmei Wang
Journal:  Int J Mol Med       Date:  2022-08-10       Impact factor: 5.314

Review 5.  Sex Steroid Receptors in Polycystic Ovary Syndrome and Endometriosis: Insights from Laboratory Studies to Clinical Trials.

Authors:  Fazilah Abdul Hamid; Muhammad Azrai Abu; Abdul Kadir Abdul Karim; Mohd Faizal Ahmad; Nor Haslinda Abd Aziz; Datu Agasi Mohd Kamal; Mohd Helmy Mokhtar
Journal:  Biomedicines       Date:  2022-07-14

6.  Wenshenyang recipe treats infertility through hormonal regulation and inflammatory responses revealed by transcriptome analysis and network pharmacology.

Authors:  Lan Xie; Shuai Zhao; Xiaoling Zhang; Wenting Huang; Liansheng Qiao; Delin Zhan; Chengmei Ma; Wei Gong; Honglei Dang; Hua Lu
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.